Eduardo Najar, Katherine Trujillo
Agencia Latina de Noticias Medicina y Salud Pública
European Sanitary Authorities approve the use and distribution of AstraZeneca’s pharmaceuticals as well as high levels of efficacy and safety
On the day of December 30, health and salvation entities will approve the emergence of a crackdown on the new coronavirus in European territory. According to the United Kingdom, a new SARS-CoV-2 pathogen named N501Y was unveiled at the N501Y. .
The approval of this vacancy, is an alert notice to the new cases that have been reported inside the United Kingdom where sober 53 53 135 new cases. The level of hospitalization occupancy is high and there are 21,500 cases, which reflect that there is a steady state of emergency records from the peak of the pandemic.
As is the case with the epidemiological crisis in the United Kingdom, there is a new pharmacy, in addition to the vacancies of Pfizer and Modern, with the AstraZeneca quiere guaranteeing the mass and human antidote process, which has contagion and transmission costs are considerably increased.
It reads “there are three strict clinical trials and an exhaustive analysis of data by MHRA experts, which concludes that the vaccine complies with the strict standards of safety, quality and efficiency”, announced the Ministry of Health in a communiqué.
The results of the studies in 24,000 people in the United Kingdom, Brazil and South Africa ensure that the AstraZeneca vaccine has 70% efficiency, a little less than the promises made by Pfizer / BioNTech and Moderna.
It is believed that AstraZeneca will be used in medium-sized and low-cost countries and that there is a low cost and summed up in this facility for refrigeration and differentiation of the other vacancies produced by the other laboratories with its competence. This vaccine will be on the market at a cost of $ 2.50 and it is hoped to produce 3,000 million doses for the finals of this year.